Neuronetics Q4 rev $22.5M (+11% YoY); closes Greenbrook TMS, guides FY25 rev $145-155M

Neuronetics, Inc.

Q4 2024 total revenue $22.5M (+11% YoY); U.S. treatment session revenue $12.9M; clinic revenue from Greenbrook $4.4M.
Net loss Q4 $(12.2)M or $(0.33) per share vs $(5.4)M or $(0.19) in Q4 2023.
Acquired Greenbrook TMS on Dec 9, 2024 adding 95 U.S. clinics; secured $10M from Perceptive Advisors at close.
Realized over $21M of $22M targeted annualized cost synergies from Greenbrook integration.
Completed $18.9M secondary offering in Feb 2025; guides FY25 rev $145-155M and Q3 2025 cash flow positive.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.